Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 20
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,892
-0.44%
|
$967,980
$65.83 P/Share
|
|
Jan 20
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,892
+1.29%
|
$59,568
$4.71 P/Share
|
|
Jan 19
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
35,000
-9.2%
|
$2,205,000
$63.86 P/Share
|
|
Jan 19
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+14.93%
|
$70,000
$2.03 P/Share
|
|
Jan 19
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,500
-0.45%
|
$352,000
$64.08 P/Share
|
|
Jan 19
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
59,986
-2.55%
|
$3,779,118
$63.74 P/Share
|
|
Jan 19
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,986
+4.82%
|
$119,972
$2.03 P/Share
|
|
Jan 19
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,136
-3.32%
|
$328,704
$64.28 P/Share
|
|
Jan 19
2021
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,704
-2.86%
|
$301,056
$64.0 P/Share
|
|
Jan 17
2021
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
872
-0.14%
|
$54,064
$62.96 P/Share
|
|
Jan 17
2021
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,073
-2.18%
|
$1,554,526
$62.96 P/Share
|
|
Jan 17
2021
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
334
-0.6%
|
$20,708
$62.96 P/Share
|
|
Jan 17
2021
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-0.18%
|
$17,174
$62.96 P/Share
|
|
Jan 17
2021
|
Thomas Altier Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
780
-0.47%
|
$48,360
$62.96 P/Share
|
|
Jan 15
2021
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
19,059
+18.06%
|
-
|
|
Jan 15
2021
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,496
-0.73%
|
$278,752
$62.96 P/Share
|
|
Jan 15
2021
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,589
+4.45%
|
-
|
|
Jan 15
2021
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,138
-0.62%
|
$442,556
$62.96 P/Share
|
|
Jan 15
2021
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,590
+4.58%
|
-
|
|
Jan 15
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
75,122
-2.17%
|
$4,657,564
$62.49 P/Share
|
|
Jan 15
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,122
+6.0%
|
$150,244
$2.03 P/Share
|
|
Jan 15
2021
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,005
-1.76%
|
$62,310
$62.96 P/Share
|
|
Jan 15
2021
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
12,706
+18.24%
|
-
|
|
Jan 15
2021
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
1,787
-1.14%
|
$110,794
$62.96 P/Share
|
|
Jan 15
2021
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
28,589
+15.43%
|
-
|
|
Jan 15
2021
|
Thomas Altier Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,604
-1.55%
|
$161,448
$62.96 P/Share
|
|
Jan 15
2021
|
Thomas Altier Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,147
+4.09%
|
-
|
|
Jan 05
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
21,468
-1.78%
|
$1,137,804
$53.6 P/Share
|
|
Jan 05
2021
|
Evan Roberts Chief Operating Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
575
-0.09%
|
$2,300
$4.71 P/Share
|
|
Jan 04
2021
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
500
-1.12%
|
$27,000
$54.26 P/Share
|
|
Jan 04
2021
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+1.1%
|
$0
$0.84 P/Share
|
|
Jan 04
2021
|
Mark Douglas Smith Director |
SELL
Open market or private sale
|
Direct |
6,000
-19.68%
|
$318,000
$53.02 P/Share
|
|
Jan 04
2021
|
Mark Douglas Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+33.13%
|
$24,000
$4.71 P/Share
|
|
Jan 04
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
80,245
-3.03%
|
$4,252,985
$53.06 P/Share
|
|
Dec 24
2020
|
Edward L Cahill Director |
SELL
Open market or private sale
|
Direct |
24,370
-25.63%
|
$1,389,090
$57.22 P/Share
|
|
Dec 17
2020
|
Cheryl Pegus |
SELL
Open market or private sale
|
Direct |
8,415
-33.41%
|
$471,240
$56.15 P/Share
|
|
Dec 16
2020
|
Cheryl Pegus |
SELL
Open market or private sale
|
Direct |
22,732
-47.44%
|
$1,250,260
$55.83 P/Share
|
|
Dec 16
2020
|
Cheryl Pegus |
BUY
Exercise of conversion of derivative security
|
Direct |
20,764
+30.23%
|
$228,404
$11.89 P/Share
|
|
Oct 23
2020
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,669
-5.12%
|
$329,422
$38.21 P/Share
|
|
Oct 23
2020
|
Thomas Altier Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,669
+4.87%
|
$0
$0.84 P/Share
|
|
Oct 22
2020
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
86,237
-34.95%
|
$3,190,769
$37.65 P/Share
|
|
Oct 22
2020
|
Thomas Altier Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,237
+25.9%
|
$0
$0.84 P/Share
|
|
Oct 21
2020
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
10,834
-17.56%
|
$379,190
$35.0 P/Share
|
|
Oct 21
2020
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
9,281
+13.07%
|
$18,562
$2.03 P/Share
|
|
Oct 12
2020
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,779
-4.05%
|
$216,928
$32.13 P/Share
|
|
Oct 12
2020
|
Thomas Altier Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,779
+3.89%
|
-
|
|
Oct 01
2020
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,774
-2.11%
|
$443,220
$30.93 P/Share
|
|
Oct 01
2020
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
4,477
-1.69%
|
$138,787
$31.38 P/Share
|
|
Oct 01
2020
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,377
+1.03%
|
$5,508
$4.71 P/Share
|
|
Sep 29
2020
|
Edward L Cahill Director |
BUY
Other acquisition or disposition
|
Direct |
24,306
+20.36%
|
-
|